EXPERT VIDEOS
All video interviews from ASCO 2019
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMartin Reck gives an overview on where we are today regarding immunotherapies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMarina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAkito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.
EXPERT VIDEOS
All video interviews from ESMO 2019
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationFilippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMichael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationStephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationIoannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.
EXPERT VIDEOS
All video interviews from ESMO 2018
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationSanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationLuis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.
EXPERT VIDEOS
All video interviews from WCLC 2018
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationHerbert Loong on peculiarities of lung cancer research with a focus on phase I studies.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJames Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMaximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationVera Hirsh discusses the latest clinical achievements using <em>EGFR</em>-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.
EXPERT VIDEOS
All video interviews from ASCO 2018
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationEdward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationBarbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.
EXPERT VIDEOS
All video interviews from ASCO 2017
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRichard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAnna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMaya Gottfried on NSCLC screening and treatment options.
EXPERT VIDEOS
All video interviews from CSCO 2017
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationCaicun Zhou discusses NSCLC care in China, and the use of molecular targeted agents
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationShun Lu discusses the recent clinical trial data for EGFR targeted agents and how this will shape clinical practice, as well as the need for solid clinical trial data revealing how the sequencing of EGFR directed agents affects survival
EXPERT VIDEOS
All video interviews from ESMO 2017
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationHossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationNicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationLecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationFilippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.
EXPERT VIDEOS
All video interviews from WCLC 2017
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationDavid Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationKeunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRamaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationPaul A. Bunn discusses current and future treatment options in lung cancer.
EXPERT VIDEOS
All video interviews from ESMO 2016
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationEnriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMartin Reck discusses the management of immunotherapy related adverse events.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationPasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAnders Mellemgaard on anti-angiogenesis treatments
EXPERT VIDEOS
All video interviews from WCLC 2016
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationMartin Schuler on the current state-of-play for EGFR diagnostic technologies
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJohan Vansteenkiste discusses the practical considerations for immunotherapy
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRobert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationFiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJames Chih-Hsin Yang talks TKIs
Videos
Impressions from participants – Preceptorship 2016 Vienna
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationParticipants of the inaugural Springer International Lung Cancer Preceptorship 2016 give their impressions of the meeting.